AstraZeneca

The ZEST trial failed to enroll enough ctDNA-positive patients for niraparib to prevent breast cancer recurrence. Lessons include starting ctDNA testing during treatment and focusing on high-risk patients. Only 40 patients were enrolled, with niraparib showing a median recurrence-free interval of 11.4 months vs. 5.4 for placebo.

AstraZeneca will cap out-of-pocket costs at $35 for its next-gen, near-zero carbon inhalers post-FDA approval. This follows Sanders urging GSK to make a similar commitment for their climate-friendly inhalers.

Moderna, a biotech company specializing in mRNA technology, developed one of the first COVID-19 vaccines and researches treatments for infectious diseases, cancer, and rare genetic disorders. Founded in 2010, it became publicly traded in 2018 and has since expanded its mRNA-based vaccine research to include RSV, HIV, and Zika fever, among others.

Tasca Therapeutics announced a $52 million Series A financing to advance its drug discovery platform, progress CP-383 into Phase 1/2 clinical studies, and expand its drug candidate pipeline. The company identifies auto-palmitoylated proteins as unique therapeutic targets across various diseases. CP-383, a first-in-class molecule, has shown robust anti-cancer activity. The executive team brings extensive experience in drug discovery and development.

FDA revoked EUA for Evusheld (tixagevimab co-packaged with cilgavimab) on Nov 21, 2024, as all lots expired and over 90% of U.S. variants were non-susceptible.

FDA revoked EUA for Evusheld (tixagevimab co-packaged with cilgavimab) on Nov 21, 2024, as all lots expired and non-susceptible variants frequency exceeded 90% in the U.S.

The ZEST trial, evaluating niraparib for breast cancer recurrence prevention, was terminated early due to low ctDNA detection post-treatment. Lessons include starting ctDNA testing during treatment and focusing on high-risk patients for future trials.

The Breakthrough Therapies Market was valued at USD 150.6B in 2024, projected to reach USD 287.5B by 2029, growing at a CAGR of 13.80%. The report analyzes BTD's risks, benefits, fast-track drug development, therapy areas, leading companies, and market dynamics.

The Global Antimicrobial Peptides Market is projected to grow from US$223.90 Mn in 2023 to US$532.02 Mn by 2031, driven by biotechnology advances and health awareness. Key players include Novozymes A/S, Pfizer Inc., and GlaxoSmithKline plc. Challenges include stringent regulations and microbial resistance.

The CRISPR and Cas gene market was valued at $3.3 billion in 2023, with a CAGR of 20.38% since 2018. It's projected to reach $8.8 billion by 2028 and $24.6 billion by 2033. Growth drivers include personalized medicine, genetic disorders, and synthetic biology. Challenges include regulatory complexities and healthcare access in developing countries. The market is segmented by type, application, product type, end use, and service type, with various segments showing significant growth potential. North America leads the market, but Asia-Pacific and Africa are expected to grow fastest. The market is dominated by large players like Danaher Corporation and Agilent Technologies Inc.